Dallas, TX: ReportsandReports announce it will carry Daiichi Sankyo Co., Ltd: PharmaVitae Profile Market Research Report in its Store.
Browse complete Daiichi Sankyo Co., Ltd: PharmaVitae Profile Report
Introduction
This analysis examines the historical and forecast performance for Daiichi Sankyo in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Daiichi Sankyo’s performance against key rivals in the prescription pharmaceutical sector
- Assess the importance of Daiichi Sankyo’s olmesartan antihypertensives franchise (Benicar, Benicar HCT and Azor) is to the company’s outlook
- Evaluate the prospects of the company’s key launch product, Effient (prasugrel) which is being co-developed with Eli Lilly
Table Of Contents
CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Financial performance, 2001-13 6
Daiichi Sankyo: PharmaVitae forecasts at a glance 7
Strategic insight 8
Introduction 8
Product strategic insight 8
Olmesartan franchise central to Daiichi Sankyo’s future growth 8
Uncertainty regarding generic entry 9
Two scenarios for olmesartan 10
Some genericization already priced into the upside scenario 13
Effient: Daiichi Sankyo’s much-needed new revenue stream 13
M&A strategic insight 15
M&A strategic insight 15
Ranbaxy acquisition 15
SWOT analysis 17
SWOT analysis 17
Strengths 17
Weaknesses 19
Opportunities 19
Threats 20
CHAPTER 3 QUARTERLY NEWS UPDATE 23
Product developments 23
Deals and alliances 24
Product deals 24
Technology deals 26
M&A activity 27
Company announcements 30
Future product milestones 34
CHAPTER 4 COMPANY INTRODUCTION 35
Key findings 35
Background 36
M&A history 36
Ranbaxy acquisition 37
Zenotech: opportunity in biopharmaceuticals 37
Current corporate structure 38
CHAPTER 5 COMPANY SALES 39
Key findings 39
Prescription pharmaceutical sales and growth rate analysis, 2001-13 40
Product analysis 42
Product analysis, 2001-07 43
Product analysis, 2007-13 46
Therapy area analysis 50
Therapy area analysis, 2001-07 51
Therapy area analysis, 2007-13 54
Therapy area focus, 2001-13 57
Geographic analysis 59
Geographic analysis, 2001-07 61
Geographic analysis, 2007-13 65
Geographic focus, 2001-13 69
Launch/core/expiry analysis 71
Explanation of launch/core/expiry analysis 71
Launch analysis, 2007-13 72
Core analysis, 2007-13 73
Expiry analysis, 2007-13 74
Launch/core/expiry configuration, 2007-13 76
Molecule type analysis 77
Molecule type analysis, 2001-07 78
Molecule type analysis, 2001-07 78
Molecule type analysis, 2007-13 80
Externalization analysis 83
Externalization analysis, 2001-07 84
Externalization analysis, 2007-13 87
CHAPTER 6 COMPANY FINANCIALS 91
Key findings 91
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 92
Financial statements, 2001-07 94
Profit and loss account, 2001-07 94
Balance sheet, 2001-07 96
Operating costs and profit analysis 98
Operating costs and profit analysis, 2001-07 99
Operating cost ratio and profit margin analysis, 2001-07 100
Operating cost ratio and profit margin analysis, 2007-13 101
Operating costs and profit analysis, 2007-13 103
Return on capital employed analysis 105
Capital employed analysis, 2001-07 106
Return on capital employed (RoCE) analysis, 2001-07 108
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 111
Key findings 111
Overview 112
Cardiovascular 113
Benicar 113
Overview 113
Sales forecast 114
Benicar HCT 116
Overview 116
Sales forecast 117
Azor 119
Overview 119
Sales forecast 120
WelChol 122
Overview 122
Sales forecast 123
Mevalotin 125
Overview 125
Sales forecast 126
Hematology 128
Effient 128
Overview 128
Sales forecast 129
Infectious diseases 131
Cravit 131
Overview 131
Sales forecast 132
Endocrine, metabolic & genetic disorders 134
Rivoglitazone 134
Overview 134
Sales forecast 135
Browse complete Daiichi Sankyo Co., Ltd: PharmaVitae Profile Report
Browse all Healthcare Market Research Reports
Browse all Datamonitor Market Research Reports RSS
Browse all Latest Report
Related Reports:
Daiichi Sankyo Co., Ltd. – SWOT Analysis
Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
